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Metabolic Profiling of IDH Mutation 
and Malignant Progression in 
Infiltrating Glioma
Llewellyn E. Jalbert1, Adam Elkhaled1,2, Joanna J. Phillips3,4, Evan Neill1, Aurelia Williams1, 
Jason C. Crane1, Marram P. Olson1, Annette M. Molinaro4,5, Mitchel S. Berger4, 
John Kurhanewicz1,2, Sabrina M. Ronen1, Susan M. Chang4 & Sarah J. Nelson1,2
Infiltrating low grade gliomas (LGGs) are heterogeneous in their behavior and the strategies used 
for clinical management are highly variable. A key factor in clinical decision-making is that patients 
with mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) oncogenes are more likely to have 
a favorable outcome and be sensitive to treatment. Because of their relatively long overall median 
survival, more aggressive treatments are typically reserved for patients that have undergone malignant 
progression (MP) to an anaplastic glioma or secondary glioblastoma (GBM). In the current study, ex vivo 
metabolic profiles of image-guided tissue samples obtained from patients with newly diagnosed and 
recurrent LGG were investigated using proton high-resolution magic angle spinning spectroscopy (1H 
HR-MAS). Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between 
astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP. Levels 
of 2-hydroxyglutarate (2HG) were correlated with increased mitotic activity, axonal disruption, 
vascular neoplasia, and with several brain metabolites including the choline species, glutamate, 
glutathione, and GABA. The information obtained in this study may be used to develop strategies for 
in vivo characterization of infiltrative glioma, in order to improve disease stratification and to assist in 
monitoring response to therapy.
Infiltrating gliomas comprise 80% of malignant brain tumors and consist primarily of astrocyte and oligoden-
drocyte cell types. Tumor grade is assessed according to criteria set by the World Health Organization (WHO)1. 
Patients diagnosed with Grade II glioma are considered to be low grade (LGG), and may survive for years or even 
decades2,3. In making decisions about clinical management, it is necessary to strike a balance between treating the 
tumor and impacting quality of life. More aggressive treatments are often reserved for tumor recurrence, when 
lesions may undergo malignant progression (MP) to Grade III (anaplastic glioma) or Grade IV glioma (secondary 
GBM)4. Unfortunately, at present, there is a significant lack of diagnostic and prognostic biomarkers that are able 
to non-invasively assess MP and predict clinical outcome.
In 2009, Yan et al. discovered novel missense mutations in the isocitrate dehydrogenase 1 & 2 (IDH1/2) onco-
genes, which are present in upwards of 70–80% of lesions that arise from low-grade lineage and confer a signif-
icant survival advantage over wild-type tumors5. Interestingly, IDH1/2 mutations were found to be conserved 
across mutually exclusive pathways of TP53 mutation and 1p19q chromosomal loss and have been implicated as 
the earliest known mutation event in gliomagenesis6. Given the limited therapeutic options available for LGGs, 
IDH mutations have garnered significant attention as a targetable therapeutic pathway with several novel thera-
pies currently in development and under investigation in clinical trials7–9.
The IDH1/2 genes natively encode the isocitrate dehydrogenase (IDH) enzymes required for the decarboxyla-
tion of isocitrate to α -ketoglutarate in the cytosol and mitochondria, respectively. The heterozygous nature of IDH 
mutations results in an amino-acid substitution at one of two enzymatic active sites, most commonly arginine 
to histidine, creating a wild-type and mutant heterodimer. The wild-type position continues the production of 
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α -ketoglutarate, while the mutant portion develops the gain-of-function ability to further convert α -ketoglutarate 
to D-2-hydroxyglutarate (2HG), an otherwise scarce metabolite in normal cells10. 2HG accumulates up to mil-
limolar concentrations in IDH-mutant tumors and drives modification to the epigenetic landscape and cellular 
processes within the tumor11.
High-resolution Magic Angle Spinning (HR-MAS) is a powerful spectroscopic technique for interrogating 
the biochemical properties of tissue12. While 2HG is readily detectable in an ex vivo setting using HR-MAS, it has 
proved to be a difficult biomarker in vivo owing to low signal-to-noise and significant overlap with neighboring 
metabolites at clinical field strengths. Our group and others have shown that metabolic differences can differen-
tiate between cancer types and histological grades13–15. Here, we further hypothesized that there are differences 
in metabolite levels for lesions that contain the IDH-mutated genotype, as well as those that have undergone MP.
The objective of this study was to characterize the ex vivo metabolic profiles from patients with a range of 
infiltrating glioma. The observed profiles were related to findings from histological analysis of sampled tissue 
with respect to variations in IDH mutation status, histological subtype, and tumor grade. The long-term goal is 
to use the information obtained as a means to design in vivo metabolic imaging methods that could improve the 
characterization of this disease, and provide biomarkers for non-invasive monitoring of disease progression and 
malignant progression in patients.
Methods
Patient population. The study was approved by the Institutional Review Board (IRB) at the University 
of California, San Francisco (UCSF). Patient accrual was performed prospectively and informed consent was 
obtained from each participating subject, with all experiments carried out in accordance to the protocols set 
by the IRB. A total of one hundred and twenty-six patients were included. Thirty-six of the patients had newly 
diagnosed, non-enhancing lesions. Ninety patients had an initial diagnosis of WHO grade II glioma and were 
presenting for surgical resection owing to suspected recurrence, when MP is commonly observed.
Presurgical in vivo MR imaging and spectroscopy. MR examinations were performed on either a 1.5 T 
or 3 T MR scanner (GE Healthcare Technologies) using an eight-channel phased-array head coil (MRI Devices). 
Standard anatomical imaging included T2-weighted (FLuid Attenuated Inversion Recovery (FLAIR) and Fast 
Spin Echo (FSE)) as well as T1-weighted pre- and post-gadolinium contrast images. Diffusion Weighted Imaging 
(DWI) was obtained in the axial plane with 6 gradient directions and two-fold acceleration with sensitivity 
encoding parallel imaging [repetition time (TR)/echo time (TE) = 1000/108 ms, voxel size = 1.7 × 1.7 × 3 mm3, 
b = 1000 s/mm2]. Dynamic Susceptibility Contrast (DSC) Perfusion Weighted Imaging (PWI) was obtained with 
a 5 ml/s bolus injection of 0.1 mmol/kg body weight gadolinium diethyltriamine pentaacetic acid (Gd-DTPA) and 
acquired using a series of T2*-weighted echo-planar images [TR/TE/Flip-angle = 1250–1500/35–54 ms/30–35 
degrees, 128 × 128 matrix, slice thickness = 3–5 mm, 7–15 slices with 60–80 time points] before, during, and 
after injection. Lactate-edited 3D proton MR spectroscopic imaging (MRSI) was acquired using point-resolved 
spectroscopic selection (PRESS) for volume localization and very selective saturation (VSS) pulses for lipid signal 
suppression [approximate excited volume = 80 × 80 × 40 mm3, TR/TE = 1104/144 ms, overpress factor = 1.5, field 
of view = 16 × 16 × 16 cm3, nominal voxel size = 1 × 1 × 1 cm3, flyback echo-planar readout gradient in the SI 
direction, 988 Hz sweep width and 712 dwell points]15.
Post processing of MR data. The MR data were de-identified and transferred to a local Linux workstation. 
Software developed in-house was applied to estimate relevant DWI, PWI, and MRSI parameters and to normal-
ize between field strengths and subjects using estimates from Normal Appearing Brain Tissue (NABT). Maps of 
the normalized Apparent Diffusion Coefficient (ADC) were generated on a voxel-by-voxel basis according to 
a published algorithm16. Perfusion datasets were non-rigidly aligned using the VTK CISG software package17. 
Normalized Cerebral blood volume (CBV), percent Δ R2* signal recovery (%-REC), Δ R2* peak height (PH), 
and recirculation factor were calculated for each voxel using software developed by our lab. CBV intensities and 
PH parameters were obtained by fitting the dynamic perfusion data by a modified gamma-variate function with 
a recirculation parameter18. Peak height and percent recovery values were also estimated using a simplified non-
parametric procedure19.
Lactate-edited MRSI data were reconstructed and the signal from the individual channels combined to 
quantify total choline (tCho), N-acetyl-aspartate (NAA), creatine (Cr), lactate (Lac) and lipid (Lip) levels. The 
choline-to-N-acetyl-aspartate index (CNI) was generated from an iterative linear regression based algorithm20 
and represents changes in choline and NAA levels relative to voxels in NABT. Imaging data were aligned to the 
post-gadolinium T1-weighted images using FMRIB’s Linear Image Registration Tool (FLIRT). Anatomic imaging 
was resampled for overlay with DWI, PWI, and MRSI and the SIVIC software package was used to select target 
locations for intra-operative tissue sampling21.
Tissue sample acquisition. Tissue sample targets were planned for each patient based on surgically acces-
sible regions with abnormally decreased ADC, decreased %-REC, increased CBV and elevated CNI. These were 
expected to represent viable regions of tumor with elevated proliferation and neovascularization. The target 
locations were designated as 5-mm-diameter spheres on co-registered MR images and transferred to the surgi-
cal navigation workstation (BrainLAB Inc.). The participating neurosurgeons were guided to these designated 
locations and tissue samples were excised if it was possible to do so safely. Samples were immediately bisected, 
with half being fixed in 10% zinc formalin, dehydrated by graded ethanols, and embedded in Paraplast Plus wax 
(McCormick Scientific) using standardized techniques for tissue processing and immunohistochemistry. The 
other half was snap-frozen in liquid nitrogen and stored at − 80 °C for analysis with 1H HR-MAS.
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Histopathology and IDH-analysis. Tissue samples were reviewed and scored for standard WHO criteria 
by a board-certified neuropathologist. Antibodies used in the assessment of the samples included rabbit pol-
yclonal MIB-1 anti-Ki67 (30-9) (Ventana Medical Systems) at 2 μ g/ml for 23 min at 37 °C; mouse anti-SMI-31 
(Covance) at 1.5 μ g/ml for 8 min at 37 °C; rabbit polyclonal Factor VIII (Dako) at 1.2 μ g/ml for 20 min at 37 °C; 
and mouse monoclonal anti-IDH1R132H (DIA H09) (Dianova) at 1:50 μ g for 32 min at 37 °C23. Heat antigen 
retrieval for MIB-1 was performed for 30 min in citrate buffer at pH 6. IDH1R132H and Factor VIII stain-
ing was performed in Tris-EDTA buffer at pH 8. Following antigen retrieval, sections were treated with 3% 
methanol-hydrogen peroxide for 16 min at 22 °C. All immunohistochemistry assays were performed on the 
Ventana Medical Systems Benchmark XT. Additionally histopathological methodology can be found in the 
Supplemental Materials.
Ex vivo HR-MAS spectroscopy. Image-guided tissue samples were transferred to a pre-chilled environ-
ment and loaded into a chilled 35-ml zirconia rotor (custom-designed by Varian) with 3 ml of 99.9% atom-D 
deuterium oxide containing 0.75 wt% 3-(trimethylsilyl) propionic acid (Sigma-Aldrich) for chemical shift ref-
erencing. Data were acquired at 11.7 T, 1 °C, 2250 Hz spin rate in a 4-mm gHX nanoprobe with a Varian INOVA 
500 MHz multinuclear spectrometer. The nanoprobe gHX is an inverse probe, optimized for the direct detection 
of protons and the indirect detection of X-nuclei (13C, 31P, 15N) and was equipped with a magic angle gradient 
coil. A rotor-synchronized T2-weighted Carr-Purcell-Meiboom-Gill (CPMG)22 pulse sequence was chosen for 
its ability to eliminate broad macromolecular signals, and run with a TR/TE = (4 s)/(144 ms), 512 scans, 40,000 
acquired points, 90° pulse, and 20 kHz spectral width for a total time of 35 min.
Preprocessing of HR-MAS spectra was done in the time domain using the Java-based magnetic resonance user 
interface (jMRUI)23. All data was normalized by tissue sample weight to correct for differences in signal intensity. 
Quantification of metabolite levels was achieved with the semi-parametric algorithm HR-QUEST, which fits a 
customized basis set of metabolites to a given spectrum24. The HR-QUEST basis set used in this study comprised 
spectra from 27 metabolites that are commonly studied in human brain tumors. Only metabolite levels with less 
than 13% Cramer-Rao error estimates were included in the analysis. Average spectral profiles were produced 
using in house algorithms that frequency-shifted and normalized each post-processed spectrum by tissue size. 
Two experienced spectroscopists evaluated each spectrum to qualitatively assess goodness of metabolite fits, the 
presence of 2HG levels, and whether low resolution or signal-to-noise compromised its analysis. Patients were 
treated as entirely IDH mutated if 2HG was determined to be present in any tissue sample spectrum or if either 
immunohistochemistry for IDH1R132H or Sanger sequencing for other variants of IDH1/2 were positive. This 
combined approach reduced the risk of false-negatives based on the other mutational variants of IDH1 and IDH2, 
which would not be detected under IHC alone.
Heatmap generation. A spectral heatmap was generated from the HR-MAS data using the following pro-
cedure: each metabolite was normalized by the 90th-percentile for relative visualization, the tissue samples were 
categorized by grade, the data were imported into Gitools version 2.2.1 (www.gitools.org)25 and a linear, hierar-
chical clustering algorithm was performed at the tissue sample level.
Statistical Analysis. All statistical testing was performed in R (version 3.1.2). Mixed effect logistic regres-
sion modeling that incorporated the effect of multiple tissue samples per patient was used to determine the signif-
icant differences in metabolite levels between different tumor grades and IDH mutation status. Measured levels 
of each metabolite were used as lone predictors for a binary outcome in the model. Odds ratios and Wald statis-
tic p values were reported together with a 95% confidence interval for each metabolite and group comparison. 
Statistical significance was assessed at p < 0.05.
The Pearson product-moment correlation test was used to assess pair-wise correlations between 2HG levels 
and other continuous variables, and for the subset of ordinal variables, a Kendell tau rank correlation was per-
formed. In order to address the multiplicity of observations in each biopsy event, each correlation was run fifty 
times with a random selection of one sample per event. The mean and standard deviation of the Tau estimates 
were reported with the median p value of all tests. To assess confounding relationships with 2HG levels and 
differences in tumor cellularity, this process was repeated after normalizing metabolite levels by cell density as 
determined by the average number of cells per 200x field. For 2HG and metabolite level correlations, a Bonferroni 
alpha-correction was used as a conservative threshold of significance at p < 0.002.
Results
Characterization of the patient population. A summary of the patient population is presented in 
Table 1. The majority of the patients (108 patients, 88%) were found to harbor IDH mutations. These lesions 
were distributed across all histological subtypes, including 52 patients with astrocytoma (AS), 44 patients with 
oligodendroglioma (OD), and 30 patients with mixed oligoastrocytoma (OA). There were 57 tissue samples from 
36 patients who had non-enhancing, newly diagnosed WHO Grade II (25 patients, 38 samples), WHO Grade III 
(9 patients, 15 samples), or WHO Grade IV glioma (2 patients, 4 samples). There were 162 tissue samples from 
90 patients with an initial diagnosis of LGG who presented at the time of suspected disease recurrence, with a 
median time to recurrence of 6.1 years. Fifty-one percent of the population was determined to be Grade III or 
Grade IV and forty-nine percent was Grade II. Of the 65 patients where clinical 1p19q chromosomal data was 
available, 36 were co-deleted, 27 remained intact, and 2 patients had deletion of the 19q arm only.
Metabolic differences associated with IDH mutation and MP. There were significant metabolic dif-
ferences in IDH-mutated lesions when compared to wild-type. Within all grades, IDH-mutated lesions were found 
to have increased levels of 2HG and decreased levels of Glu and GABA compared to wild-type lesions (Table 2). 
Within Grade II and Grade III lesions, there were elevations of free choline (Cho), glycerophosphocholine (GPC), 
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PC, and the combined measure of tCho in IDH-mutated lesions. Addditionally, we found significant elevations 
of several metabolites in samples from lesions that had undergone MP. The magnitude of the observed differ-
ences varied based on tumor grade and histological subtype as presented in Fig. 1 and Table 2. Figure 2 presents 
comparisons of averaged spectra based on IDH status (plot A), as well as upon the grade of glioma at the time 
of surgery (plots B and C). Lesions that had undergone MP displayed statistically significant elevations of phos-
phocholine (PC) and total choline (tCho). Elevated levels of taurine (Tau) were associated with secondary Grade 
III and Grade IV lesions, and elevated levels of hypo-taurine (hTau) with secondary Grade IV lesions. Increased 
glycine (Gly), glutamate (Glu), glutathione (GSH), alanine (Ala), aspartate (Asp), and betaine (Bet) were found 
to be significantly elevated in lesions that had undergone MP to Grade IV compared with all other grades, while 
glutamine (Gln) and glucose (Glc) were elevated in secondary Grade IV tumors relative to Grade II lesions. 2HG 
levels were elevated in secondary Grade IV lesions across all histologies. A spectral heatmap produced from the 
dataset is presented in Fig. 3, and displays normalized spectral intensities across all tissue samples. Intra-grade 
clustering provided visualization of the entire population and distribution of metabolite levels in individual 
samples.
When assessed by AS or OD histological subtype, there were distinct differences in MP for each tumor type, 
which are presented in Supplementary Table S1. Anaplastic ASs displayed marked elevations of PC and Cho, 
while anaplastic ODs displayed elevations of GPC. In AS lesions, increased phosphoethanolamine (PE) and Gln 
were observed in Grade III versus Grade II samples, while elevated glutamate was observed in secondary Grade 
IV samples. 2HG was found to be elevated in secondary Grade IV lesions and Grade III oligodendrogliomas. 
Other metabolites that were increased in anaplastic OD included Tau, Gly, Gln, and Bet. Supplementary Figure S1 
presents differences between AS and OD histological types for samples from Grade II and III lesions. In OD 
Grade/Hist
Total patients 
(samples)
IDH-wt 
(samples)
IDH-mut 
(samples)
IDH-uncertain 
(samples)
All 126 (219) 15 (26) 108 (190) 3 (3)
II 62 (103) 10 (16) 50 (85) 2 (2)
III 50 (89) 2 (4) 47 (84) 1 (1)
IV 14 (27) 3 (6) 11 (21) —
AS 52 (83) 8 (12) 42 (69) 2 (2)
OA 30 (57) 5 (10) 24 (46) 1 (1)
OD 44 (79) 2 (4) 42 (75) —
Table 1.  Patient and tissue sample population by grade at the time of surgery, histological subtype, 
and IDH mutation status. The patient population comprised astrocytoma, oligodendroglioma, and 
oligoastrocytoma histological subtypes. The majority of patients (88%) harbored IDH-mutant lesions and 64 
patients (51%) had undergone MP. It is of note that 10 of the patients were scanned at two distinct recurrences.
All histologies (med ± SE) All histologies (med ± SE)
Metabolite IDH-mut IDH-wt Grade II Grade III GBM
Cho Cho 7.4 ± 1.26 3.72 ± 0.73 — — —
GPC 20.2 ± 3.64 9.2 ± 2.09 — — —
PC 11.54 ± 3.0 6.58 ± 1.37 9.38 ± 1.68 14.26 ± 5.04 26.44 ± 15.08
tCho 38.18 ± 5.81 21.03 ± 3.16 23.05 ± 5.01 36.31 ± 9.37 64.27 ± 18.48
GSH — — 11.52 ± 1.54 12.76 ± 4.51 17.28 ± 7.06
hTau — — 2.05 ± 0.63 — 4.07 ± 0.77
Tau — — 14.87 ± 2.3 31 ± 4.24 29.6 ± 10.1
2HG 8.17 ± 1.01 2.82 ± 0.47 5.43 ± 1.1 7.88 ± 1.57 13.7 ± 2.57
Glu 49.84 ± 4.99 94.18 ± 33.03 41.76 ± 6.17 52.18 ± 8.13 79.79 ± 24.65
Gln — — 33.09 ± 5.64 — 38.24 ± 15.39
Glc — — 31.31 ± 5.12 — 35.74 ± 44.41
Ala — — 11.73 ± 2.31 17.12 ± 9.49 20.87 ± 10.88
Asp — — 37.83 ± 4.89 39.33 ± 5.83 71.32 ± 27.7
GABA 2.92 ± 0.42 6.48 ± 3.04 — — —
Gly — — 33.46 ± 5.67 46.12 ± 8.57 78.03 ± 29.75
Bet — — 0.85 ± 0.1 0.88 ± 0.18 1.27 ± 0.6
Table 2.  Statistically significant metabolite levels of all histologies between IDH status and tumor grade. 
Mixed-effects logistical regression results demonstrated significant differences in various metabolite levels 
between IDH genotype and tumor grades (p < 0.05). Metabolite levels are presented for statistically significant 
metabolites at a tissue sample level. These results are presented as median spectral areas for each metabolite as fit 
by HR-QUEST.
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tumors, there was elevated PC and Cho in Grade II samples, increased 2HG and GPC in Grade III samples, and 
elevated Eth when Grade II and III samples were combined. Mixed oligoastrocytomas were excluded from histo-
logical subtype analysis due to the uncertainty in how to classify them in the absence of 1p and 19q chromosomal 
information.
Correlation of 2HG with metabolite levels and histopathology parameters. Given that the study 
population was predominately IDH-mutated, this provided a unique opportunity to investigate correlations of 
2HG levels with other brain tumor metabolites and histopathology parameters in these tumors. These results are 
presented in Table 3. There were positive correlations of 2HG levels with all of the choline-containing compounds 
(Cho, GPC, PC, and tCho), PE, GSH, Tau, Glu, Gln, Asp, myo-I, SI, GABA, PCr/Cr, Gly, Bet, and Thr. In addition, 
there were correlations with 2HG levels and mitotic activity, as measured by MIB1 antibody staining; increased 
axonal disruptions, as measured by SMI-31; and the decreased presence of normal, delicate brain vasculature, and 
the increased presence of simple vascular hyperplasia, as measured by Factor VIII endothelial staining.
Discussion
This study identified distinctive metabolic profiles for gliomas according to the status of IDH mutation, histolog-
ical subtype, and malignant progression. Several metabolites including those comprising the in vivo total choline 
peak, as well as glutamate and glutamine, were correlated with levels of 2HG and histopathological parameters. 
The results obtained in this project provide improved characterization of the metabolic pathways in these lesions, 
and given that many of these metabolites are measurable in vivo, may be of use for improving the non-invasive 
assessment and monitoring of patients.
When considering all histological subtypes, choline-containing compounds were found to be elevated in sam-
ples from lesions that had undergone progression. Previous studies in our group have shown increases in PC 
associated with Grade III and primary Grade IV lesions13. These results show that tCho was also elevated and may 
serve an in vivo biomarker for MP. The association of AS lesions with PC and Cho, and OD lesions with GPC may 
Figure 1. Flow diagram of metabolite differences associated with IDH mutation status and MP. Here we 
present the metabolic differences associated with IDH mutation versus wild-type lesions, as well as profile 
differences associated with malignant progression across all histologies, as well as within individual astrocytoma 
and oligodendroglioma subtypes. Within IDH-mutated lesions, we found significant elevations in 2HG, 
and found decreases in Glu and GABA versus wild-type. When assessing Grade II and III lesions, we found 
increases in the choline species associated with the IDH genotype. Further, we found several metabolite levels 
to be increased in tumors that had undergone MP versus those that did not, including specific differences 
associated with MP within distinct histological subtypes.
www.nature.com/scientificreports/
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reflect alterations in the phospholipid metabolism found in the choline kinase pathway for individual subtypes. 
While a general increase of total choline has been associated with higher-grade lesions as well as the OD subtype, 
the differences in choline-species between distinct histologies was previously unknown and warrants additional 
investigation.
Increases in Glu and Gln that were associated with progression to GBM may be a product of elevated glut-
aminolysis, which leads to an additional production of alanine and aspartate26. Considering that Glu, Gln, Ala, 
and Asp were elevated in Grade IV lesions, these metabolites may present another avenue for monitoring patients 
with MRSI. The recent advent of hyperpolarized 13C spectroscopic imaging and successes of many novel hyper-
polarized imaging-agents such as [1-13C] pyruvate, [1-13C] glutamate, and [1-13C] α -ketoglutarate may provide 
additional promising approaches to investigate this pathway, in addition to that of the IDH mutation27–29.
The production of reactive oxygen species (ROS) promotes genomic instability in tumors and glutathione is 
one of several molecules involved in eliminating ROS. While its role in brain tumors remains to be elucidated, it 
appears to play a role in therapeutic sensitivity and resistance30. Increased production of GSH in samples eval-
uated in the current study may be linked to the increased oxidative stress, disregulation of the GSH pathway, or 
treatment related changes in high-grade lesions. Within the context of IDH-mutated gliomas, studies in GBM 
cell lines have observed a decrease in GSH in cells that artificially overexpress the IDH mutation31,32, which has 
been hypothesized as a possible mechanism for the radiosensitivity observes in these lesions. However, our results 
Figure 2. Averaged HR-MAS spectral profile from IDH mutation status and MP across different 
histological grades. Results were normalized by tissue weight to produce an averaged spectrum at the tissue 
sample level for IDH genotypes and individual grades. IDH-mutated spectral profiles demonstrate increased 
2HG, Cho, GPC, PC, and tCho and decreased Glu and GABA (A), while many metabolites were elevated in 
tumors that had undergone MP (B,C).
www.nature.com/scientificreports/
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demonstrate a positive correlation between 2HG and GSH levels, suggesting that perhaps there may be alternate 
cellular mechanisms that require further investigation.
Glycine and other amino-acid metabolites have been previously reported to be elevated in Grade IV lesions33, 
and are consistent with the demands for nucleotide synthesis present in highly proliferative cells. The results of 
this study corroborate the prior data and further demonstrate significantly elevated Gly in anaplastic oligoden-
drogliomas. As this metabolite is measurable using in vivo techniques, Gly should be explored as a biomarker for 
MP in olidodendroglioma.
Prior works by our group in a subset of fifty-two patients from this study compared LGG metabolism with 
that of primary and recurrent GBM13, as well as established that the elevation of 2HG in IDH-mutated lesions 
was detectable using magnetic resonance34. This latter work was corroborated by others35,36 and laid the necessary 
groundwork for this metabolomic HR-MAS investigation between tumors of different IDH status and histological 
subtypes. Given the equilibrium between alpha-ketoglurate and glutamate in the glutamate-glutamine cycle37, it 
has been predicted that there would be a decrease in glutamate in IDH-mutated tumors, but this has been diffi-
cult to assess using in vivo methods, which suffer from significant limitations in resolution and signal-to-noise. 
The results from our study provide confirmation that there are reductions in glutamate in IDH-mutated lesions, 
as well as reductions in GABA, the production of which is tightly linked with available pools of glutamate and 
glutamine. When we evaluated the Grade II and Grade III lesions together, we also found elevations in all of the 
choline-species, including the total choline peak, in IDH-mutated tumors.
While the previous comparison characterized differences between wild-type and IDH-mutated lesions, we 
further sought to evaluate IDH-mutated tumors specifically and the correlation between levels of 2HG and other 
metabolites and histopathology features. Within IDH-mutated tumors, we found many metabolites including 
glutamate and GABA that were positively correlated with increased 2HG levels. In order to reduce any potentially 
confounding effects created by differences in tumor cellularity, we normalized these levels by average cell density. 
To our surprise, these results held significant, therefore the metabolite differences observed cannot be explained 
by differences in tumor cellularity alone. Interestingly, the correlation between 2HG levels and mitotic activity, 
axonal disruption, and neovascularization, further suggestive that high levels of 2HG may be associated with 
malignant progression, and that these cells could be sensitive to therapeutics targeted to these properties.
Figure 3. Metabolic spectral heatmap across samples categorized by IDH mutation, histological subtype, 
and grade at the time of surgery. The heatmap was generated from the HR-QUEST quantification of individual 
tissue sample spectra (rows) and organized by metabolite (columns). Data were normalized by the 90th-
percentile across columns and sorted by PC within each grade providing comprehensive visualization of the 
entire dataset and distribution of metabolite levels across subtype and histological grades. We observed intra-
patient heterogeneity of tissue samples, as well as global elevation in the key metabolites associated with IDH 
mutation, histological subtype, and MP.
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It is important to highlight that there have been previous in vivo studies that have investigated the relation-
ships between IDH mutation and cellularity, which have yielded similar results. Specifically, the results of our 
project corroborated the in vivo study by Pope et al.38, which found elevations in total choline and mitotic activity 
in IDH-mutated tumors. The results obtained by De La Fuente, et al.39, however, recently reported correlation 
between 2HG levels and cell density, but not mitosis. This may be explained by the decreased sensitivity of in vivo 
techniques in detecting 2HG in small to medium sized lesions, and highlights the gains in sensitivity associated 
with high-resolution NMR. These results suggest increased cellular pathology associated with 2HG production 
and that total choline may serve as a promising in vivo biomarker for assessing the increased cellularity associated 
with IDH mutation.
Owing to the rarity of IDH2 mutations, which occur in approximately 3% of diffuse gliomas40, this study has 
treated the various mutated residues of IDH1 and IDH2 collectively. In 2011, Reitman et al. established that a 
majority of the metabolic alterations of IDH mutations were shared across mutations in IDH1 and IDH2 when 
compared with wild-type gliomas31. Subsequent in vitro work has revealed differential 2HG production based on 
the subcellular localization of IDH2 enzymes in the mitochondria, providing evidence that IDH2 mutations are 
robust to the absence of the wild-type enzyme while IDH1 mutations are not41. Although limited in sample size, a 
recent in vivo study at ultra-high field strength supports this result by demonstrating an over three-fold increase 
in 2HG levels in IDH2-mutated lesions42–45. Taken together, these studies support further investigation into the 
metabolic differences between IDH1 and IDH2 mutations that are downstream of 2HG.
There is a clear need for diagnostic and treatment biomarkers for the IDH-pathway that can keep pace with 
the development of novel therapies. While measuring 2HG using in vivo spectroscopic techniques would likely 
provide the most specific marker for these lesions, the clinical development and determination of the optimal 
sequence is still under active investigation. While the approaches presented thus far are promising, achieving the 
necessary spatial resolution and signal-to-noise for defining tumor margins, as well as reliably resolving 2HG from 
overlapping metabolites, such as GABA, remains challenging. Given the strong correlations of levels of 2HG with 
levels of metabolites such as choline, creatine and glutamate, which are routinely measured using in vivo 1H MRSI 
and are present in higher concentrations, a combined approach may be valuable for evaluating treatment effects.
The ultimate goal of this work is to improve the clinical management of patients with glioma. The spectral 
profiles obtained in this study may aid in developing non-invasive MRSI methods to better diagnose and monitor 
patients based on underlying tumor metabolism, and further characterize the IDH-mutated molecular subtype. 
Most importantly, we hope that this study will lead to improved outcome and quality of life for these patients.
Variable correlated
Correlation 
type
Number of 
pairs p value
Cho + 62 p < 0.001
GPC + 70 p < 0.001
PC + 60 p < 0.001
tCho + 70 p < 0.001
PE + 58 p < 0.001
GSH + 43 p < 0.001
Tau + 30 p < 0.001
Glu + 66 p < 0.001
Gln + 62 p < 0.001
Asp + 46 p < 0.001
myo-I + 64 p < 0.001
SI + 39 p < 0.001
GABA + 35 p = 0.001
PCr/Cr + 69 p < 0.001
Gly + 55 p < 0.001
Bet + 45 p < 0.001
Tbr + 48 p < 0.001
Mitosis (MIB1) + 55 p = 0.016
Axonal disruption (SMI31) + 53 p = 0.032
Simple vascular neoplasia + 49 p = 0.01
Complex vascular neoplasia + 54 p = 0.047
Table 3.  Metabolite and histopathology correlations with 2HG levels. Each of the study parameters 
correlated with 2HG is presented as determined from Pearson testing for all continuous variables and Kendell 
Tau testing for ordinal variables. Here we present the correlated parameters with their associated number of 
tested pairs and median p values. Normalization by cell density did not affect any correlation within IDH-
mutant tumors.
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